Axsome Therapeutics, Inc. (AXSM) |
|
71.96 1.23 (1.74%)
|
09-26 15:33 |
|
Open: |
70.73 |
Pre. Close: |
70.73 |
|
High:
|
73.165 |
Low:
|
70.585 |
|
Volume:
|
306,494 |
Market Cap:
|
3,528(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 3:17:37 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 91.59 One year: 97.29 |
| Support: |
Support1: 70.52 Support2: 58.68 |
| Resistance: |
Resistance1: 78.42 Resistance2: 83.3 |
| Pivot: |
76.49  |
| Moving Average: |
MA(5): 73.01 MA(20): 77.34
MA(100): 75.76 MA(250): 68.16 |
| MACD: |
MACD(12,26): -1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 9.3 %D(3): 12.5 |
| RSI: |
RSI(14): 41.8 |
| 52-week: |
High: 91.29 Low: 38.86 |
| Average Vol(K): |
3-Month: 742 (K) 10-Days: 736 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXSM ] has closed above bottom band by 22.3%. Bollinger Bands are 10% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
73.57 - 74.07 |
74.07 - 74.48 |
|
Low:
|
69.6 - 70.07 |
70.07 - 70.46 |
|
Close:
|
70.04 - 70.8 |
70.8 - 71.44 |
|
Company Description |
|
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. |
Headline News |
Tue, 26 Sep 2023
Mizuho Reiterates Axsome Therapeutics (AXSM) Buy ... - Nasdaq
Tue, 26 Sep 2023
Axsome Therapeutics Inc (AXSM) is lower by -1.27% in a Week, Should You Hold? - InvestorsObserver
Mon, 25 Sep 2023
Analyst Ratings for Axsome Therapeutics - Axsome Therapeutics ... - Benzinga
Mon, 25 Sep 2023
Optimistic Outlook for Axsome Therapeutics Analysts Predict ... - Best Stocks
Fri, 22 Sep 2023
Axsome Therapeutics Joins the Global Narcolepsy Community in ... - BioSpace
Thu, 14 Sep 2023
Is Axsome Therapeutics Inc (AXSM) a Winner in the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
35 (M) |
|
% Held by Insiders
|
17.1 (%) |
|
% Held by Institutions
|
70.6 (%) |
|
Shares Short
|
8,240 (K) |
|
Shares Short P.Month
|
9,060 (K) |
Stock Financials |
|
EPS
|
-4.41 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.96 |
|
Profit Margin (%)
|
-101.1 |
|
Operating Margin (%)
|
-88.9 |
|
Return on Assets (ttm)
|
-25.6 |
|
Return on Equity (ttm)
|
-125.5 |
|
Qtrly Rev. Growth
|
429.5 |
|
Gross Profit (p.s.)
|
0.97 |
|
Sales Per Share
|
3.86 |
|
EBITDA (p.s.)
|
-3.39 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-111 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
-16.43 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
12.13 |
|
Price to Sales
|
18.72 |
|
Price to Cash Flow
|
-30.66 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
